aTyr Pharma (NASDAQ:ATYR) Earns Market Perform Rating from Leerink Partners

Key Points

• aTyr Pharma's stock has received a **"market perform"** rating from Leerink Partners, maintaining consistency amidst fluctuating analyst opinions.
• The company's shares have seen mixed ratings, with **Wells Fargo raising its price target from $17 to $25** and additional revisions from other firms affecting overall consensus ratings.
• aTyr Pharma's stock suffered a decline on Monday, trading at **$1.12**, down by **$4.92**, highlighting current volatility in its market performance.

aTyr Pharma (NASDAQ:ATYR - Get Free Report)'s stock had its "market perform" rating restated by Leerink Partners in a report issued on Monday, Marketbeat reports.

Several other analysts have also recently issued reports on the stock. Cantor Fitzgerald cut shares of aTyr Pharma from an "overweight" rating to a "neutral" rating in a research note on Monday. HC Wainwright reiterated a "buy" rating and issued a $35.00 price objective on shares of aTyr Pharma in a research report on Wednesday, June 4th. Wall Street Zen cut aTyr Pharma from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Wells Fargo & Company raised their price target on aTyr Pharma from $17.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, June 20th. Finally, Jefferies Financial Group raised their price target on aTyr Pharma from $9.00 to $17.00 and gave the company a "buy" rating in a report on Friday, August 22nd. One analyst has rated the stock with a Buy rating and six have issued a Hold rating to the company's stock. According to MarketBeat, the stock currently has a consensus rating of "Hold" and a consensus target price of $23.25.

aTyr Pharma Stock Performance

Shares of NASDAQ:ATYR traded down $0.06 during trading on Monday, hitting $0.99. 26,835,154 shares of the company were exchanged, compared to its average volume of 4,180,764. The stock has a 50 day moving average of $5.02 and a 200 day moving average of $4.30. The company has a market cap of $97.21 million, a PE ratio of -1.24 and a beta of 1.01. The company has a debt-to-equity ratio of 0.01, a current ratio of 5.63 and a quick ratio of 5.63. aTyr Pharma has a 52-week low of $0.95 and a 52-week high of $7.29.

aTyr Pharma (NASDAQ:ATYR - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). As a group, equities research analysts predict that aTyr Pharma will post -0.91 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the company. Northern Trust Corp purchased a new position in shares of aTyr Pharma in the fourth quarter valued at about $661,000. Jane Street Group LLC purchased a new position in aTyr Pharma during the 4th quarter valued at $720,000. Bank of America Corp DE purchased a new position in aTyr Pharma during the 4th quarter valued at $330,000. Balyasny Asset Management L.P. purchased a new position in shares of aTyr Pharma during the fourth quarter valued at about $160,000. Finally, Group One Trading LLC purchased a new position in shares of aTyr Pharma during the fourth quarter valued at about $26,000. 61.72% of the stock is owned by hedge funds and other institutional investors.

aTyr Pharma Company Profile

aTyr Pharma, Inc engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.